Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation  by Brekke, Pål H. et al.
Respiratory Medicine (2008) 102, 1243e1247ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedUnderdiagnosis of myocardial infarction
in COPD e Cardiac Infarction Injury Score (CIIS)
in patients hospitalised for COPD exacerbationPa˚l H. Brekke*, Torbjørn Omland, Pa˚l Smith, Vidar SøysethDepartment of Medicine and Faculty Division, Akershus University Hospital, N-1478 Lørenskog, Norway
Received 16 November 2007; accepted 6 April 2008
Available online 1 July 2008KEYWORDS
COPD;
Myocardial infarction;
Electrocardiogram;
Cardiac Infarction Injury
Score;
Prevalence* Corresponding author. Tel: þ47 67
E-mail addresses: pal.brekke@m
(P. Smith), vidar.soyseth@medisin.uio
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.04.010Summary
Background: Patients with chronic obstructive pulmonary disease (COPD) are usually former or
current smokers, and are at increased risk of ischemic heart disease. We used Cardiac Infarc-
tion Injury Score (CIIS) to assess the prevalence of prior myocardical infarction (MI) in COPD
patients and compared this to clinicians’ previous diagnosis of MI.
Methods: From the hospital database, 897 patients (mean age 70.9 years, 50.8% female)
discharged after treatment for COPD exacerbation in the years 2000e2003 were identified.
Disease history was established from medical records and the hospital patient database. Elec-
trocardiograms from the day of admission were available in 827 patients, and were coded
according to the CIIS algorithm by an investigator blinded to clinical and outcome data. The
CIIS score was validated using follow-up data for the first year after discharge.
Results: Two hundred and twenty-nine patients had CIIS 20, out of whom only 30% (95%
confidence interval: 24e36%, nZ 68) had a recognised history of MI. Female patients had
a lower probability of diagnosis despite ECG evidence. Validation of CIIS using multivariate
Cox regression analysis showed that a score 20 had independent prognostic value for the first
year after discharge, with an adjusted HR of 1.52 (1.14e2.03).
Conclusion: Unrecognised MI is common in patients hospitalised with COPD exacerbation. Less
than one-third of patients with ECG evidence of previous MI by the CIIS system actually have
the diagnosis in their medical records.
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Chronic obstructive pulmonary disease (COPD) is a common
and debilitating disease, the pathophysiological hallmark of
which is airflow limitation, caused by airway inflammation.1
COPD is one of the very few diseases that still has a rising
mortality rate worldwide.2
At least since 1976, whenFriedman andcoworkers showed
an association between lung function and risk of myocardial
infarction (MI),3 it has been known to physicians that cardiac
comorbidity in COPD patients is common. In recent years,
there has been increasing awareness among clinicians and
researchers that cardiovascular disease is a significant con-
tributor to morbidity and mortality in COPD patients.4e6
The clinical diagnosis of cardiovascular disease in COPD
patients may be elusive. Exercise capacity may be limited by
impaired lung function, concealing coronary symptoms, and
while symptoms such as chest pain and dyspnea are common
during COPD exacerbations, they may be interpreted as
COPD related even when their origin is cardiac. Based on
death certificates and adjudication of medical records,
estimates of ischemic heart disease prevalence vary in the
range of 10e40%.7e9 There is reason to believe that cardiac
comorbidity in COPD patients is underdiagnosed.
In their review of the relationship between reduced lung
function and cardiovascular mortality,5 Sin and coworkers
found an intriguing association between Forced Expiratory
Volume in 1 s (FEV1) and changes in the electrocardiogram
(ECG) as measured with a scoring system called Cardiac
Infarction Injury Score (CIIS) in COPD outpatients. CIIS is an
epidemiological tool designed to discriminate between the
presence and absence of MI based on a standard 12-lead
ECG, and has been reported to have a specificity of 98% for
detecting MI at a score of 20 points or higher.10 The prognos-
tic value of CIIS has been validated in healthy populations,11
hypertensive patients,12 and in the post-MI setting.13
There are, however, no published papers on CIIS and
COPD exacerbations. The primary objective of the present
study was to determine the prevalence of MI, as assessed by
CIIS, in patients hospitalised for COPD exacerbation, and to
compare this with the diagnosis of MI from patients’
medical records. A secondary objective was to validate
the prognostic value of CIIS in COPD patients.
Methods
The study population consisted of patients discharged from
Akershus University Hospital, a 700-bed teaching hospital,
after treatment for COPD exacerbation. Patients aged 40
years or older who were admitted during the four-year
period from 1 January 2000 to 31 December 2003, and who
were discharged with a primary diagnosis of COPD exacer-
bation, ICD 10 (International Classification of Diseases, 10th
revision) code J44.0 or J44.1, or COPD (J44.x) as an
underlying diagnosis combined with pneumonia (J13-J18.9)
as the main diagnosis, were studied. Patients with previous
diagnoses of sarcoidosis, interstitial lung disease, or neuro-
muscular disease, or who received a secondary diagnosis of
acute MI during the index admission, were excluded. For
patients with more than one admission during the inclusion
period, the latest admission date was used. A total of 1087admissions satisfied inclusion and exclusion criteria. Forty-
one patient records were not available for manual review.
Fifty cases of erroneous ICD coding (5%) were discovered
during manual record review. Data for the 897 patients
discharged alive were used in this study. For the purpose of
validating the prognostic value of CIIS, we used follow-up
data until death or 30 June 2005, whichever occurred first.
ECGs recorded on admission were retrieved from pa-
tients’ records. Seventeen discrete features of the ECG
were manually measured and tabulated, and later con-
verted to a score according to a CIIS algorithm. Several
versions of the CIIS algorithm exist e the present study used
the version modified for visual coding published by Dek-
ker.14 Right ventricular hypertrophy was defined according
to NOVACODE criteria.15 Heart rate and rhythm were gath-
ered from the ECG. ECG coding was performed by physi-
cians blinded to the outcome of interest. Seventy patients
with irretrievable or illegible ECGs were excluded from
further analyses.
Intra- and inter-rater agreement of the CIIS scoring was
performed by randomly selecting 70 ECGs for re-measure-
ment by the primary rater (PHB) and by a medical student
blinded to the study hypothesis and the CIIS algorithm (ALS).
The patients’ medical record were manually searched
for a history of MI. Additionally, each patient’s discharge
ICD codes since 1987, until but not including the date of
admission, were obtained from the hospital database, and
MIs thus identified were added. A history of percutaneous
coronary intervention (PCI) or coronary artery bypass graft
surgery (CABG) and atrial fibrillation was gathered in the
same manner. History of cancer, diabetes, hypertension
and congestive heart failure was compiled from 1987 to
2003 discharge ICD codes.
Spirometry data, if performed in a stable state at least
one week before or four weeks after hospital discharge,
were gathered from patient records. Forced vital capacity
(FVC), Expiratory Volume in 1 s (FEV1), height and weight
were recorded, and body mass index (BMI), defined as
weight in kilograms divided by the square of height in
meters, was calculated. FVC and FEV1 values are expressed
as percent of predicted using the European Community for
Steel and Coal equations.16 FEV1% of predicted and BMI
were dichotomised at the 25th/75th percentile.
All statistical analyses were performed using Stata/SE
version 8.2 software (StataCorp LP, Texas, USA). Ninety-five
percentage confidence intervals (CI) are given in parenthe-
ses. All-cause mortality data, gathered from the Central
National Register, was used as the outcome measure in the
validation analysis. Multivariate analysis was performed
using Cox proportional hazards regression. The proportional
hazard assumption was visually tested using logelog plots.
Results are reported as hazard ratio (HR) for Cox analyses.
The study was approved by the Data Inspectorate and
the Regional Committee for Research Ethics.Results
Mean age at discharge was 70.9 years, and 50.8% were
female. Baseline data are presented in Table 1. After
discharge, cumulative survival was 75.6% and 65.2% at one
and two years, respectively. Only 55 patients (6%) had never
Table 1 Baseline characteristics of 827 patients by CIIS
score
CIIS< 20
(nZ 598)
CIIS 20
(nZ 229)
Clinical data, mean (SD)
Age (years) 69.9 (10.8) 74.6 (9.8)
Female, n (%) 328 (55) 93 (41)
FEV1% 47.3 (20.0) 46.4 (18.3)
FVC% 72.0 (22.6) 71.1 (23.1)
Heart rate (beats/min) 96.3 (20.0) 98.0 (19.8)
BMI 24.4 (5.5) 23.9 (5.3)
Atrial fibrillation, n (%) 49 (8) 42 (18)
Medical history, n (%)
Previous infarction 61 (10) 68 (30)
CAGB 12 (2) 13 (6)
PCI 13 (2) 5 (2)
Heart failure 36 (6) 45 (20)
Hypertension 122 (20) 50 (22)
Diabetes 63 (11) 36 (16)
Thromboembolism 16 (3) 3 (1)
Cancer 78 (13) 30 (13)
Ex-smoker 51 (9) 27 (12)
Never smoker 35 (6) 13 (6)
Medication use at discharge, n (%)
Beta-blockers 76 (13) 25 (11)
ACEI or ARB 107 (19) 63 (29)
Statins 75 (13) 35 (16)
Warfarin 43 (8) 32 (15)
Acetylsalicylate 147 (26) 64 (29)
CIIS e Cardiac Infarction Injury Score; FEV1% e Forced Expira-
tory Volume in 1 s in percent of predicted; FVC% e forced vital
capacity in percent of predicted; BMI e body mass index; CABG
e coronary artery bypass graft surgery; PCI e percutaneous
coronary intervention; ACEI e angiotensin converting enzyme
inhibitors; ARB e angiotensin receptor blockers.
Table 2 Percentage of patients (95% confidence interval)
with previously recognised myocardial infarction, by
characteristic
Characteristic CIIS 20
Gender
Male (%) 38 (30e47)
Female (%) 17 (10e26)
Age group
<60 (%) 20 (6e44)
60e69 (%) 21 (9e36)
70e79 (%) 34 (25e45)
>80 (%) 31 (21e43)
Medical history
Diabetes (%) 25 (12e42)
Hypertension (%) 44 (30e59)
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among these, 604 (87%) had FEV1/FVC-ratio 0.7.
Incomplete or complete right bundle branch block (RBBB)
was observed in 50 patients. Ninety-one patients had atrial
fibrillation (acute or chronic), and 30 had signs of right
ventricular hypertrophy according to NOVACODE criteria.
The CIIS score was very nearly normally distributed, with
a mean score of 13.4 points (standard deviation (SD): 11.6).
Men had slightly higher mean scores at 14.9 (SD: 11.9) vs
females at 12.0 (SD: 11.3). The prevalence of heart disease
in general, and specifically a history of previous myocardial
infarction, increased with CIIS score.
When using a CIIS cut-off value of 20 points, 27.7% of
patients in this study had had an MI according to the ECG.
On the other hand, the prevalence of MI diagnosis accord-
ing to ICD codes and medical records was 15.6%.
Of the 229 patients with ECG signs of previous infarction,
30% (CI: 24e36%, nZ 68) had a recognised history of MI,
compared to 10% (CI: 8e13%, nZ 61) of 598 patients with
a CIIS below the cut-off. When using a cut-off CIIS value
of 30 points, the proportions changed to 36% (CI: 25e47%,
nZ 29) and 13% (CI: 11e16%, nZ 100), respectively.Female patients and younger age groups were less likely
to have an established MI diagnosis despite ECG evidence
of a previous infarction, whereas patients with known hy-
pertension had a higher likelihood of diagnosis. Separate
percentages for subgroups of patients at a CIIS cut-off of
20 points are shown in Table 2.
For CIIS dichotomised at 20 points, the intra-rater kappa
was 0.84, and the inter-rater kappa was 0.88. Average
difference in discrete measured ECG features was less than
0.2 mm (0.02 mV on the amplitude scale or 4 ms on the time
scale), average difference in scores between raters was 0.7
(pZ 0.3). Disagreement was most common in ECGs with
a noisy baseline.
Because CIIS may be influenced by the presence of other
conditions, we performed analyses on further restricted
datasets, first excluding patients with right ventricular
hypertrophy, then patients with disease history or signs
associated with an elevated probability of pulmonary
embolism (history of thromboembolic disease, atrial ar-
rythmia, RBBB) were excluded. Results of these restricted
analyses are presented in Table 3.
Finally, as CIIS has not been validated in COPD patients,
we investigated the prognostic value of elevated CIIS in the
first year after discharge. The unadjusted HR for CIIS 20
was 1.98 (1.50e2.61). Fig. 1 shows a KaplaneMeier survival
curve for patients with CIIS 20 vs patients with CIIS< 20.
Adjusting for age, gender, spirometry values, history of
heart failure, diabetes and cancer, elevated CIIS remained
a highly significant independent predictor of mortality, with
an adjusted HR of 1.52 (1.14e2.03). The model did not vio-
late the proportional hazards assumption.
Discussion
We have found that a large proportion of COPD patients has
electrocardiographic evidence of previous MI, but has never
been diagnosed with one. In this study, 15.6% of patients
had a recognised history of MI, whereas ECG evidence
suggests a prevalence of nearly twice that. Of patients with
MI according to CIIS, less than one-third (30%) actually had
an established MI diagnosis. Among female patients, the
proportion of recognised MIs was only 17%.
Table 3 Percentage of patients (95% confidence interval)
with previously recognised myocardial infarction after pro-
gressive restriction of the cohort
Excluded patients In analysis
(n)
CIIS 20
(%)
Right ventricular hypertrophy 797 31 (25e37)
þAtrial fibrillation 710 31 (25e39)
þRight bundle branch block 682 32 (25e39)
þHistory of thromboembolic
disease
668 32 (25e39)
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patients involved, the large proportion of available ECG
recordings, and the magnitude of the findings. Further-
more, the fact that a high CIIS score has independent
prognostic value in this population adds credibility to the
score’s ability to discriminate between patients with and
without significant comorbidity.
In the study on the association between CIIS and lung
function by Sin and coworkers,5 they found a mean score of
10 points in COPD outpatients with ‘‘moderate’’ (FEV1 50e
80% of predicted) and 11.2 in patients with ‘‘severe’’
(FEV1< 50% of predicted) airways obstruction. The higher
mean score of 13.4 in our group of hospitalised patients cor-
responds well with their more advanced disease and gener-
ally more pronounced airways obstruction. We were not,
however, able to confirm the same association between
COPD severity and CIIS score as Sin and Man e this may
be explained by a greater variability in the timing of spi-
rometry measurements relative to the ECG date in our pa-
tient group.
Hemodynamic changes related to COPD, such as in-
creased pulmonary vascular resistance and increased right
ventricular workload, cause changes in the ECG. Patients
with obvious acute ECG changes would probably receive
a heart disease related primary diagnosis, and thus not be
included in our cohort in the first place, but more subtle
changes may also influence the score. While the CIIS does
not include ST-segment changes in the algorithm, we have
accounted for the possibility of such effects on the scoringFigure 1 KaplaneMeier survival curve for CIIS 20 vs
CIIS< 20.system by restricting analyses to a group without known
confounders, and also by raising the cut-off value at which
we counted the ECG changes as a possible infarction to 30
points, without significantly affecting our findings.
The ECG evaluation in this study was performed visually,
whereas other investigators have used computer algorithms
to evaluate electronic ECGs. Since the investigator was
blinded to clinical data, the visual coding should not
introduce a bias in the data, but it may have resulted in
less precision than an automated procedure. Any such non-
differential misclassification would, however, cause an
under-estimation of the effect of CIIS.
We used ICD codes and manual searching of medical
records to establish whether a patient had a previous
diagnosis of MI. The database of diagnoses goes back to
1987. It is possible that patients may have had an MI at
another hospital, and that the diagnostic code has not been
included in our system at later visits. We believe, however,
that the MI diagnosis has a fairly high ‘‘impact’’, and that
by the combination of database and manual searching for
the mention of MI in the patient records, we have been able
to register most of the established MI diagnoses.
Several previous studies have shown that patients with
COPD have an increased risk of cardiovascular dis-
ease.4,17,18 Few papers report on MI or IHD prevalence in
COPD patients. Using the Saskatchewan Health database,
Curkendall et al. reported a period prevalence for MI of
2.3% for a one-year observation time.18 This corresponds
quite well with the cumulative prevalence of diagnoses in
our cohort (16%), which is based on a longer observation pe-
riod. A study by van Manen and coworkers found that 15.6%
of persons with an FEV1< 70% of predicted had self-
reported heart disease.19 While Antonelli-Incalzi and co-
workers20 report a perhaps surprisingly low 10% prevalence
of IHD diagnosis in their study of patients with severe COPD
(mean FEV1 34%) hospitalised for exacerbation, they also
found that 21% of patients had ECG evidence of IHD, sup-
porting the hypothesis that heart disease in this patient
population remains unrecognised.
Epidemiological studies have shown that unrecognised
MI is prevalent in general populations; Kannel and Abbott
reported that 25% of a Framingham population had unrec-
ognised MI,21 and de Torbal et al. found that one-third to
one-half of MIs in a general population in Rotterdam re-
mained clinically unrecognised.22 To the best of our knowl-
edge, the present study is the first to address
underdiagnosis of MIs in a population of COPD patients.
The diagnosis of COPD in this study was made at
discharge, based on all available clinical data. A physician
specialised in internal medicine or pulmonary medicine
verified the diagnoses. While the diagnosis was not based
on specific criteria such as suggested by the Global
initiative for chronic Obstructive Lung Disease (GOLD), we
consider the study population to be well defined, and
representative of COPD patients seen in pulmonary care
units in Western countries.1 Norway is one of the very few
countries where smoking is more prevalent among females
than males,23 which explains the high percentage of female
patients in our study.
In conclusion, our study suggests that MI is frequently
unrecognised in patients hospitalised for COPD exacerba-
tion. Less than one-third of patients with evidence of
Underdiagnosis of MI in COPD 1247previous MI by the CIIS ECGsystem actually have the diagnosis
in their medical records. Furthermore, CIIS has prognostic
value in the first year after discharge. The relationship
between COPD and ischemic heart disease highlights the
need for further studies to illuminate pathophysiological
mechanisms and assess the effect of therapy.
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